Marian Laderoute, Ph.D. Medical Sciences - Immunology

As the Research Manager of the Blood Zoonotics Unit in the Blood Safety Program, Dr. Laderoute was the lead discoverer at the Public Health Agency of Canada (PHAC) of human endogenous retrovirus K102 (HERV-K102) as a replication competent, protector foamy retrovirus unique to humans which may protect against RNA pandemic viruses such as HIV-1 (2007, 2015). Worldwide patent applications were submitted by PHAC but fortunately, have since been abandoned. Thus, anyone can now exploit this important discovery for pandemic control without fear of patent infringements, no matter where in the world they live.

It was TRULY a major feat that I am very proud of to invoke worldwide patent applications by PHAC (around March 2006) and then have them abandoned (by 2012). This was critical in my view to ensure that Big Pharma and/or USA DoD could not obtain assignment of the patents with the sole purpose to bury the use of such technology for humanitarian purposes such as in safe and effective responses to pandemics.

Dr. Laderoute has experience in the regulation of biological blood products at Health Canada and in post-market surveillance of biologics namely monoclonal antibodies. Her investigation in 2007 into the mounting serious adverse events including the doubling of myocardial infarction risks every two months of patients taking efalizumab (Raptiva, a psoriasis biologic that targeted macrophages) and tough questions starting with day one, undoubtedly contributed to its suspension on Feb 27, 2009 in Canada and Europe and voluntary withdrawal from the worldwide market on June 8, 2009.

Dr. Laderoute is a global expert in trained (innate) immunity and immunosenescence (of macrophages) involving the production of HERV-K102 protective particles in foamy macrophages and sebocytes (specialized foamy macrophages of sebaceous glands) in the oral mucosa. She writes on this substack on how immunosenescence and/or SARS-CoV-2/spike protein can abort trained (innate) immunity leading to increased risks of COVID-19 severity (and other diseases).

Her focus is on pandemic responses and the many marvels of how HERV-K102 particle production promotes the survival of Homo sapiens even when facing pandemics or other forms of human extinction (allegedly the mRNA gene therapy vaccine bioweapons).

It is vitally important to realize that the immunosenescence of macrophages aside from the loss of immunosurveillance against tumors and infectious agents is causally related to age and stress associated chronic illness whether it is cancer, heart disease, type 2 diabetes, Alzheimers disease, other neurodegenerative diseases, autoimmunity, and so on.

Signs and symptoms of hypertension lasting beyond 8 days, elevated hs-CRP and even an elevated neutrophil/lymphocyte count significantly over 2 might indicate the presence of disease causing immunosenescence and/or progressing cardiovascular disease and ‘turbo’ cancers.

Accordingly, Dr. Laderoute advocates for monitoring blood pressure on a weekly and where necessary, daily basis. For potential concerns about shed spike protein (see below) when persistent elevations in blood pressure (lasting beyond 8 days) are discovered, then the protocols for reversal of high blood pressure involving AFP antagonists such as: ivermectin (or a potential substitute artemisinin), nattokinase/bromelin, vitamin D3, zinc, and isoflavonoids (60 mg per day) should be invoked [see also FLCCC I-recover protocols for complicated cases].

Dr. Laderoute also advocates for the annual (no cost) testing of vitamin D3 and DHEA (not DHEA-S) blood levels in January of each year.

(Dr. Laderoute has advanced registered technology (ART) certification in medical laboratory technology in immuno-hematology).

She published her ‘New Immunosenescence Paradigm’ in 2015 in Discovery Medicine which defined immunosenescence of macrophages as the failed lytic release of HERV-K102 particles from foamy macrophages.

She was a Brighton Collaboration, Viral Vector Vaccines SAFETY Working Group Member from 2008-2015 (set up in response to findings of negative vaccine efficacy involving enhanced infection rates in several HIV-1 vaccine RCTs ). She subsequently authored "Clues to Finding Correlates of Risk/Protection for HIV-1 vaccines, 2018" (doi:10.12688/f1000research.11818.2).

Thus, pandemic responses, pandemic vaccinology and biologics safety has been long term professional interests, concerns and duties of Dr. Laderoute.

Since August 2022 Dr. Laderoute has been warning that the pandemic now consists of COVID-19 mRNA gene therapy vaccine toxicity, morbidity, and mortality.

However by mRNA gene therapy ‘shedding’ of spike RNA/cDNA potentially through hitchhiking a ride with the HERV-K102 particles from sebocytes (specialized foamy macrophages in sebaceous glands constitutively producing and releasing HERV-K102 particles to the mucosal surfaces by lysis), there are now concerns that the spike mRNA gene therapy (mRNA and fragmented cDNA) shots might be causing more deaths than perhaps SARS-CoV-2 in the vaccinated and unvaccinated!

In terms of the mRNA gene therapy vaccines being bio-weapons the reader is referred to the substack post at https://hervk102.substack.com/p/the-marvels-of-the-herv-k102-virus. Dr. Laderoute formally called for the banning of all mRNA gene therapy vaccines on March 5, 2024 (including the establishment of clinical trial moratoriums) in the recognition that they are ‘bioweapons’ and may be inadvertently culling human populations.

Most remarkably in this substack post of March 5, 2024 and as further evidence of the suitability of the HERV-K102 protector system for pandemics, is the evidence that the broad induction of heterologous protection against C19 and non-C19 mortality following one dose in the vaccinated elders in the UK (which peaked in February 2021) also correlated with peak protection against C19 and non-C19 mortality in the unvaccinated. This observation is consistent with the horizontal shedding of protector (and clean) HERV-K102 particles from the vaccinated to the unvaccinated after the first dose which could pre-activate interferon responses and induce HERV-K102 particle production in the yet uninfected host.

Details of the potency of the HERV-K102 virus anti-virus INNATE immunity protection system of foamy macrophages in terms of pandemics have been published on the Preprint server: Laderoute, M. Antibody Dependent Enhancement (ADE) of Infection into Macrophages Validates the Importance of HERV-K102 Particle Production for Pandemic Preparedness. Preprints 2023, 2023120185. https://doi.org/10.20944/preprints202312.0185.v1

Dr. Laderoute is a champion of innate immunity vaccines over adaptive immunity vaccines for use during pandemics. Populations should consider strengthening ‘trained innate immunity’ (aka the HERV-K102 virus-anti-virus protection system she discovered at PHAC against pandemic RNA viruses) by preventing and reversing immunosenescence (see The HERV-K Way to Keep COVID-19 at Bay released on March 5, 2020 (LinkedIN) reposted to substack on February 26, 2022:

______________________________________

________________________________

and ensuring one has optimal Vitamin D levels (see articles at hervk102@substack.com and IMAGE 1 below).

IMAGE 1. Sufficient blood vitamin D3 (range of 50 to 75 ng/ml) may block the risks associated with SARS-CoV-2 virion, vaccinal gene therapy mRNA/cDNA encoding spike protein sequences, and/or spike protein liberated from the upper respiratory tract (URT) from entering and causing the conversion of the protector LB-FMs (precursor the intermediate monocytes in PBMCs) to the dysfunctional LB+FMs (precursor the non-classical monocytes in PBMCs).

Note according to the Cleveland Clinic data, there is no conversion of the spike specific IgG1/3 in the upper respiratory tract to IgG4, so any spike protein released from the URT can similarly cause the conversion of tissue macrophages and blood monocytes to become the dysfunctional macrophages and monocytes which are no longer protective (LB+FMs and non-classical monocytes). Patterson BK et al, 2022 have shown that spike protein variably accumulates in the non-classical monocytes (representing 2 to over 40% of such cells) in the blood of patients with Post Acute SARS-CoV-2 (PASC) infection.

Interestingly, alpha-fetoprotein (AFP) antagonists which reverse immunosenescence in foamy macrophages such as Vitamin D3, zinc, flavonoids, and even ivermectin [1] are used in the early treatment protocols for COVID-19. It is also suspected that artemisinin like ivermectin, could also be a dual AFP and SARS-CoV-2 spike protein antagonist and thus, very useful as key armaments against future pandemics (so stock up).

Dr. Laderoute’s goal is to awaken the world to novel and remarkable, potent innate immune mechanisms of foamy macrophages that are designed by nature to handle emerging or pandemic viruses and which protect at the individual and population based levels. This novel protection system reinforced by optimal blood levels of vitamin D3 (and/or DHEA), can also be exploited to treat and/or prevent tumors, cancers and other diseases associated with (or not) the mRNA gene therapy shots.

_________________________

1. Laderoute MP. https://openheart.bmj.com/content/8/1/e001655.responses#ivermectin-may-prevent-and-reverse-immunosenescence-by-antagonizing-alpha-fetoprotein-and-downmodulating-pi3k-akt-mtor-hyperactivity

Subscribe to HERV-K102 and Pandemic Responses

HERV-K102, trained innate immunity, immunosenescence, & CRITICAL protection against pandemics.

People

Discoverer at PHAC of HERV-K102 as a protector foamy virus of humans putatively against pandemic RNA viruses and author of the new immunosenescence paradigm 2015 affecting foamy macrophages/sebocytes/HERV-K102 and innate immunity.